Does the media favor LRMR or ATAI?

In the previous week, Atai Beckley had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Atai Beckley and 3 mentions for Larimar Therapeutics. Atai Beckley's average media sentiment score of 0.63 beat Larimar Therapeutics' score of 0.63 indicating that Atai Beckley is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LRMR or ARDX?

In the previous week, Ardelyx had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Ardelyx and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.63 beat Ardelyx's score of 0.51 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, LRMR or COAG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A Hemab Therapeutics N/A N/A N/A N/A N/A

Is LRMR or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% Hemab Therapeutics N/A N/A N/A

Does the media favor LRMR or COAG?

In the previous week, Hemab Therapeutics had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 5 mentions for Hemab Therapeutics and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.63 beat Hemab Therapeutics' score of 0.38 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, LRMR or AVBP?

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is LRMR or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% ArriVent BioPharma N/A -48.98% -45.44%

Does the media prefer LRMR or AVBP?

In the previous week, ArriVent BioPharma had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 5 mentions for ArriVent BioPharma and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.63 beat ArriVent BioPharma's score of 0.42 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LRMR or IMCR?

In the previous week, Larimar Therapeutics and Larimar Therapeutics both had 3 articles in the media. Immunocore's average media sentiment score of 1.57 beat Larimar Therapeutics' score of 0.63 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Larimar Therapeutics (LRMR) Competitors

$3.66 +0.16 (+4.57%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$3.99 +0.33 (+8.91%)

As of 06/26/2026 07:59 PM Eastern

Compare

LRMR vs. ATAI, ARDX, COAG, AVBP, and IMCR

Should you buy Larimar Therapeutics stock or one of its competitors? MarketBeat compares Larimar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Larimar Therapeutics include Atai Beckley (ATAI), Ardelyx (ARDX), Hemab Therapeutics (COAG), ArriVent BioPharma (AVBP), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.

How does Larimar Therapeutics compare to Atai Beckley?

Larimar Therapeutics (NASDAQ:LRMR) and Atai Beckley (NASDAQ:ATAI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Larimar Therapeutics has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 26.8% of Atai Beckley shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Larimar Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Larimar Therapeutics has higher earnings, but lower revenue than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Atai Beckley	$4.09M	476.19	-$660.05M	-$2.23	N/A

Larimar Therapeutics presently has a consensus price target of $13.50, indicating a potential upside of 268.85%. Atai Beckley has a consensus price target of $16.00, indicating a potential upside of 202.46%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Larimar Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Atai Beckley had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Atai Beckley and 3 mentions for Larimar Therapeutics. Atai Beckley's average media sentiment score of 0.63 beat Larimar Therapeutics' score of 0.63 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Larimar Therapeutics and Atai Beckley tied by winning 8 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Ardelyx?

Larimar Therapeutics (NASDAQ:LRMR) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Ardelyx has higher revenue and earnings than Larimar Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Ardelyx	$407.32M	3.36	-$61.60M	-$0.23	N/A

Larimar Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

In the previous week, Ardelyx had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Ardelyx and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.63 beat Ardelyx's score of 0.51 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Ardelyx	-13.58%	-38.11%	-11.85%

Larimar Therapeutics currently has a consensus target price of $13.50, indicating a potential upside of 268.85%. Ardelyx has a consensus target price of $15.73, indicating a potential upside of 184.14%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Larimar Therapeutics is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Larimar Therapeutics and Ardelyx tied by winning 8 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Hemab Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A

Larimar Therapeutics currently has a consensus target price of $13.50, indicating a potential upside of 268.85%. Hemab Therapeutics has a consensus target price of $41.40, indicating a potential upside of 27.90%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Larimar Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Hemab Therapeutics had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 5 mentions for Hemab Therapeutics and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.63 beat Hemab Therapeutics' score of 0.38 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Hemab Therapeutics	N/A	N/A	N/A

91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Larimar Therapeutics beats Hemab Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Larimar Therapeutics compare to ArriVent BioPharma?

Larimar Therapeutics (NASDAQ:LRMR) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, ArriVent BioPharma had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 5 mentions for ArriVent BioPharma and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.63 beat ArriVent BioPharma's score of 0.42 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ArriVent BioPharma's return on equity of -48.98% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Larimar Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Larimar Therapeutics currently has a consensus price target of $13.50, indicating a potential upside of 268.85%. ArriVent BioPharma has a consensus price target of $43.14, indicating a potential upside of 26.89%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Larimar Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Larimar Therapeutics beats ArriVent BioPharma on 8 of the 14 factors compared between the two stocks.

How does Larimar Therapeutics compare to Immunocore?

Larimar Therapeutics (NASDAQ:LRMR) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Larimar Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

In the previous week, Larimar Therapeutics and Larimar Therapeutics both had 3 articles in the media. Immunocore's average media sentiment score of 1.57 beat Larimar Therapeutics' score of 0.63 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Immunocore has higher revenue and earnings than Larimar Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Immunocore	$400.02M	3.93	-$35.51M	-$0.55	N/A

Larimar Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Immunocore	-6.68%	-7.07%	-2.55%

Larimar Therapeutics presently has a consensus price target of $13.50, indicating a potential upside of 268.85%. Immunocore has a consensus price target of $56.71, indicating a potential upside of 83.66%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Larimar Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Larimar Therapeutics beats Immunocore on 8 of the 15 factors compared between the two stocks.

Get Larimar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LRMR vs. The Competition

Export

Metric	Larimar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$380.21M	$3.04B	$7.05B	$12.19B
Dividend Yield	N/A	1.87%	2.66%	6.11%
P/E Ratio	-1.78	19.54	26.13	24.16
Price / Sales	N/A	330.40	555.66	102.80
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	3.89	4.21	10.78	6.38
Net Income	-$165.67M	$64.45M	$3.58B	$337.00M
7 Day Performance	0.60%	2.22%	2.22%	0.10%
1 Month Performance	4.87%	-0.77%	-0.09%	-1.28%
1 Year Performance	20.79%	29.70%	34.39%	27.68%

Larimar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LRMR Larimar Therapeutics	2.4465 of 5 stars	$3.66 +4.6%	$13.50 +268.9%	+20.8%	$380.21M	N/A	N/A	30	News Coverage High Trading Volume
ATAI Atai Beckley	3.2607 of 5 stars	$4.05 -0.2%	$16.00 +295.1%	+140.5%	$1.49B	$4.09M	N/A	80	News Coverage Analyst Forecast Options Volume
ARDX Ardelyx	2.5565 of 5 stars	$6.37 +5.3%	$15.73 +146.9%	+50.0%	$1.49B	$427.68M	N/A	90	News Coverage
COAG Hemab Therapeutics	4.7062 of 5 stars	$31.74 +8.5%	$41.40 +30.4%	N/A	$1.48B	N/A	N/A	72	News Coverage Analyst Forecast
AVBP ArriVent BioPharma	2.3917 of 5 stars	$32.70 +3.0%	$43.38 +32.6%	+48.4%	$1.48B	N/A	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LRMR) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Larimar Therapeutics (LRMR) Competitors

LRMR vs. ATAI, ARDX, COAG, AVBP, and IMCR

How does Larimar Therapeutics compare to Atai Beckley?

Summary

How does Larimar Therapeutics compare to Ardelyx?

Summary

How does Larimar Therapeutics compare to Hemab Therapeutics?

Summary

How does Larimar Therapeutics compare to ArriVent BioPharma?

Summary

How does Larimar Therapeutics compare to Immunocore?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Larimar Therapeutics (LRMR) Competitors

LRMR vs. ATAI, ARDX, COAG, AVBP, and IMCR

How does Larimar Therapeutics compare to Atai Beckley?

Is LRMR or ATAI more profitable?

Do insiders and institutionals believe in LRMR or ATAI?

Which has more risk and volatility, LRMR or ATAI?

Which has preferable earnings and valuation, LRMR or ATAI?

Do analysts rate LRMR or ATAI?

Does the media favor LRMR or ATAI?

Summary

How does Larimar Therapeutics compare to Ardelyx?

Which has better valuation and earnings, LRMR or ARDX?

Which has more risk & volatility, LRMR or ARDX?

Does the media favor LRMR or ARDX?

Is LRMR or ARDX more profitable?

Do analysts rate LRMR or ARDX?

Do institutionals & insiders believe in LRMR or ARDX?

Summary

How does Larimar Therapeutics compare to Hemab Therapeutics?

Which has higher earnings & valuation, LRMR or COAG?

Do analysts rate LRMR or COAG?

Does the media favor LRMR or COAG?

Is LRMR or COAG more profitable?

Do institutionals and insiders believe in LRMR or COAG?

Summary

How does Larimar Therapeutics compare to ArriVent BioPharma?

Do institutionals & insiders believe in LRMR or AVBP?

Does the media prefer LRMR or AVBP?

Is LRMR or AVBP more profitable?

Which has more volatility & risk, LRMR or AVBP?

Which has higher valuation and earnings, LRMR or AVBP?

Do analysts prefer LRMR or AVBP?

Summary

How does Larimar Therapeutics compare to Immunocore?

Which has more volatility and risk, LRMR or IMCR?

Does the media prefer LRMR or IMCR?

Which has higher valuation and earnings, LRMR or IMCR?

Is LRMR or IMCR more profitable?

Do analysts rate LRMR or IMCR?

Do insiders & institutionals have more ownership in LRMR or IMCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools